Osler Diagnostics appoints John Sperzel as Chief Executive Officer
Oxford, UK – 21 January 2026: Osler Diagnostics (‘Osler’ or ‘the Company’), a medical diagnostics company, today announces the appointment of John Sperzel as Chief Executive Officer.
John succeeds Connor Campbell, who co-founded Osler in 2017 and will remain on the Board of Directors, continuing to be closely involved with the business.
This leadership transition comes at a critical inflection point for Osler, as the Company shifts from a predominantly R&D-led organisation towards one focused on commercial execution. Under John’s leadership, Osler will take its breakthrough Osler Origin® platform through remaining regulatory processes, launch into the market, and execute major commercial activity.
John brings more than 30 years of executive leadership experience across the global point-of-care diagnostics industry, including having served as Chief Executive Officer of Chembio Diagnostics and Accriva Diagnostics (a Werfen company), and as President of Axis-Shield, prior to its acquisition by Abbott. Earlier in his career, he held senior point-of-care leadership roles at Bayer Diagnostics (now Siemens Healthineers), Instrumentation Laboratory (Werfen), and Boehringer Mannheim (now Roche Diagnostics). John joins Osler from Vivid Dx, an Oxford-based diagnostics company, where he served as CEO.
Connor co-founded Osler in 2017 and, as CEO, led the development of the Osler Origin® platform, the creation of a strong intellectual-property portfolio, and the build-out of Osler’s manufacturing, quality, and regulatory capabilities. He also scaled the organisation to more than 150 employees and raised over £145 million from leading institutional and strategic investors.
Connor has been an exceptional leader since co-founding Osler in 2017, successfully positioning the Company at the forefront of point-of-care diagnostics. As we now move into a phase of commercial execution, Connor and the Board determined it was beneficial to strengthen the team with additional commercial and operational leadership, and I am delighted to welcome John as our new CEO. John’s extensive diagnostics experience makes him ideally suited to lead Osler in this next phase. With John’s leadership and Connor’s continued involvement, Osler is well positioned for the future.
David Berry
As Osler transitions from an R&D-led organisation to one focused on commercial execution, it is critical that the Company has the right commercial and operational leadership in place. I am delighted to welcome John as CEO and am confident he is the right leader to support Osler’s next stage of growth. I look forward to working in close partnership with him and the wider team to support Osler through its next phase.
Connor Campbell
The Osler Origin® has the power to redefine healthcare by enabling anyone, anywhere, to access, understand, and act on their health with confidence. I am deeply impressed by the strength of the technology and the exceptional calibre of the team behind it. Osler has built a highly differentiated platform in point-of-care diagnostics, and I am excited to join as CEO, work closely with Connor and the team, and apply my experience to accelerate Osler’s next phase of growth and innovation.
John Sperzel
About Osler
Osler is a UK-based diagnostics company whose purpose is to enable anyone, anywhere, to access, understand, and act on their health.
Osler has developed the Osler Origin® – a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin® will offer a wide portfolio of diagnostic tests and serve all major healthcare settings, globally.
Osler was formed out of the University of Oxford in 2017, following decades of research from the same department that invented the portable electrochemical blood glucose sensor.
The Company is headquartered in Oxford, UK, employs approximately 150 staff and is backed by leading investors.
For more information, please visit www.oslerdiagnostics.com